The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Spravato (esketamine) has possible interactions with alcohol, some other drugs, and certain supplements. Examples include Adderall and benzodiazepines such as clonazepam (Klonopin). Talk with your ...

The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and 52% cheaper to meet its value ...

Both drugs were given on top of standard antidepressants to patients wo had failed a least two earlier treatments. Spravato has been approved since 2019 for TRD, with its label extended the ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

Ketamine is often viewed more as a party drug than a medicine. One Columbia clinic is using the drug to help patients with ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Blessing Outpatient Behavioral Health Services is offering a new option for depression. As many as 40% of people with depression can find no relief for their condition.

Intake assessments, Spravato, TMS therapy, integration therapy and medication management are eligible for insurance coverage depending on your plan and location. We also offer interest-free in ...